April Webinar: IASLC Lung Cancer Grand Rounds Series - Chemotherapy for advanced NSCLC: state-of-the-art in 2014.

IASLC 2013 Annual Report now available. 

We are a global network of specialists working together to conquer lung and thoracic cancers worldwide.

Chicago Multidisciplinary Symposium in Thoracic Oncology. Abstract submission deadline May 7, 2014.

Researchers

ELCC 2014: Lung adenocarcinoma with RET fusion: early experience with diagnosis and targeted therapy

Video

Drs. Oliver Gautschi and Lukas Bubendorf discourse on the presence of RET aberrations in NSCLC.

ELCC 2014: Late and Chronic Toxicities of New Targeted Therapies

Video

Dr. Tony Mok, President of IASLC, offers an overview on most common toxicities related to targeted therapies in NSCLC.

ELCC 2014: Clinical Utility of miRNA Signature in Plasma of Smokers Included in LD-CT Lung Cancer Screening

In search of non-invasive biomarkers

A group of researchers from Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, retrospectively evaluated a non-invasive plasma miRNA signature classifier in prospectively collected samples from smokers within the randomised Multicentre Italian Lung Detection (MILD) trial.

Practitioners

ELCC 2014: Late and Chronic Toxicities of New Targeted Therapies

Video

Dr. Tony Mok, President of IASLC, offers an overview on most common toxicities related to targeted therapies in NSCLC.

ELCC 2014: Lung adenocarcinoma with RET fusion: early experience with diagnosis and targeted therapy

Video

Drs. Oliver Gautschi and Lukas Bubendorf discourse on the presence of RET aberrations in NSCLC.

ELCC 2014: Clinical Utility of miRNA Signature in Plasma of Smokers Included in LD-CT Lung Cancer Screening

In search of non-invasive biomarkers

A group of researchers from Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, retrospectively evaluated a non-invasive plasma miRNA signature classifier in prospectively collected samples from smokers within the randomised Multicentre Italian Lung Detection (MILD) trial.

Patients

ELCC 2014: Lung adenocarcinoma with RET fusion: early experience with diagnosis and targeted therapy

Video

Drs. Oliver Gautschi and Lukas Bubendorf discourse on the presence of RET aberrations in NSCLC.

ELCC 2014: Late and Chronic Toxicities of New Targeted Therapies

Video

Dr. Tony Mok, President of IASLC, offers an overview on most common toxicities related to targeted therapies in NSCLC.

ELCC 2014: Clinical Utility of miRNA Signature in Plasma of Smokers Included in LD-CT Lung Cancer Screening

In search of non-invasive biomarkers

A group of researchers from Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, retrospectively evaluated a non-invasive plasma miRNA signature classifier in prospectively collected samples from smokers within the randomised Multicentre Italian Lung Detection (MILD) trial.